Vafidemstat
An overview of the drug Vafidemstat
| Vafidemstat | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Vafidemstat is a novel pharmaceutical drug under investigation for its potential therapeutic effects in various neuropsychiatric disorders. It is classified as a histone deacetylase inhibitor (HDAC inhibitor), which modulates the expression of genes by altering the acetylation status of histones.
Mechanism of Action[edit | edit source]
Vafidemstat functions primarily as an HDAC inhibitor. By inhibiting histone deacetylases, it increases the acetylation of histone proteins, leading to a more relaxed chromatin structure and increased gene expression. This mechanism is thought to underlie its potential therapeutic effects in neuropsychiatric disorders by modulating the expression of genes involved in neurotransmission, neuroplasticity, and inflammation.
Therapeutic Applications[edit | edit source]
Vafidemstat is being investigated for its use in treating a variety of neuropsychiatric conditions, including:
The drug's ability to modulate gene expression may help alleviate symptoms associated with these disorders by restoring normal patterns of neuronal activity and connectivity.
Clinical Trials[edit | edit source]
Vafidemstat is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are designed to assess its impact on symptom severity, cognitive function, and overall quality of life in patients with neuropsychiatric disorders.
Side Effects[edit | edit source]
As with many HDAC inhibitors, potential side effects of Vafidemstat may include:
Ongoing clinical trials aim to further elucidate the safety profile of Vafidemstat.
Research and Development[edit | edit source]
The development of Vafidemstat is part of a broader effort to create targeted therapies for complex neuropsychiatric conditions. By focusing on epigenetic modulation, researchers hope to provide more effective treatments with fewer side effects compared to traditional psychotropic medications.
Related Pages[edit | edit source]
Vafidemstat
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
